Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 44 | 0 | 1 | 0 | €216.30 | €251.80 | 16.413% |
| Neurocrine Bioscience | 36 | 0 | 5 | 0 | €135.15 | €143.34 | 6.063% |
| Acadia Pharmaceuticals | 29 | 1 | 1 | 0 | €17.64 | €31.28 | 77.379% |
| United Therapeutics | 24 | 0 | 3 | 0 | €310.20 | €299.42 | -3.476% |
| Ultragenyx Pharmaceutical Inc. | 23 | 1 | 1 | 0 | €41.60 | €86.28 | 107.401% |
| Ionis Pharmaceuticals Inc. | 26 | 5 | 6 | 0 | €47.38 | €56.86 | 20.013% |
| Halozyme Therapeutics Inc. | 20 | 0 | 0 | 0 | €51.78 | €55.13 | 6.477% |
| Iovance Biotherapeutics Inc. | 22 | 2 | 1 | 0 | €8.52 | €26.25 | 207.911% |
| Exelixis Inc. | 20 | 0 | 2 | 0 | €21.53 | €26.01 | 20.791% |
| Arrowhead Pharmaceuticals Inc. | 21 | 2 | 4 | 0 | €26.67 | €54.98 | 106.153% |
| Medpace Holdings Inc | 16 | 0 | 6 | 0 | €351.70 | €418.12 | 18.886% |
| Repligen Corp. | 13 | 0 | 0 | 0 | €129.75 | €182.96 | 41.010% |
| Xencor Inc. | 14 | 1 | 0 | 0 | €19.60 | €31.70 | 61.717% |
| Charles River Labs Intl | 12 | 0 | 1 | 0 | €215.10 | €248.57 | 15.560% |
| Amicus Therapeutics Inc. | 7 | 0 | 0 | 0 | €9.45 | €17.64 | 86.642% |
| Agios Pharmaceuticals Inc. | 8 | 1 | 0 | 1 | €44.40 | €48.75 | 9.796% |
| PTC Therapeutics Inc. | 14 | 9 | 1 | 0 | €30.60 | €41.46 | 35.500% |
| Nektar Therapeutics | 4 | 1 | 1 | 0 | €1.26 | €2.40 | 90.627% |
| Catalent Inc. | 1 | 0 | 0 | 0 | €53.88 | €55.00 | 2.079% |
| Blueprint Medicines Corp | 1 | 0 | 0 | 0 | €103.35 | - | - |
| Emergent Biosolutions Inc. | 4 | 3 | 1 | 0 | €12.87 | - | - |
| Novocure Ltd | 1 | 1 | 0 | 0 | €17.20 | - | - |